✦ LIBER ✦

B.3 Risk-benefit assessment of dopamine agonists

✍ Scribed by W.H. Oertel; C. Möller; M. Unger; K. Eggert

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical risk–benefit assessment of dopa

✍ J. C. Möller; K. M. Eggert; M. Unger; P. Odin; K. R. Chaudhuri; W. H. Oertel 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 191 KB

A reassessment of risks and benefits of

✍ Angelo Antonini; Eduardo Tolosa; Yoshikuni Mizuno; Mitsutoshi Yamamoto; Werner H 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 136 KB

Benefit-Risk of Agonist-Antagonist Analg

📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 235 KB

Risk : benefit assessment of old medicin

✍ Silvio Garattini; Vittorio Bertelé 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB

Benefit–risk assessment of vitamin D sup

✍ H. A. Bischoff-Ferrari; A. Shao; B. Dawson-Hughes; J. Hathcock; E. Giovannucci; 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 469 KB

Integrated benefit–risk assessment of fo

✍ H. Verhagen⁎; J.M. Luteijn; B.C. White; S.R.B.M. Eussen; C.J.M. Rompelberg; J. H 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 56 KB